

Univ.-Prof. Dr. med. Dobromir Dobrev, FIACS, FISHR

Director of Institute of Pharmacology, Faculty of Medicine, University Duisburg-Essen, Germany

Education and Degrees

1985-1988	Medical studies, Medical University Pécs, Hungary
1988-1992	Medical studies, Dresden University of Technology, Dresden University of Technology
1994	MD (Dr. med., magna cum laude), Dresden University of Technology
1998	Board certified ("Facharzt") in Pharmacology&Toxicology
2002	Facultas docendi ("Privatdozent") and Venia legendi in Pharmacology&Toxicology

Professional Career

1992-1994	"Arzt im Praktikum", Dept. of Clinical Pharmacology, Dresden University of Technology
1994-2008	Postdoctoral Fellow, Dept. of Pharmacology&Toxicology, Dresden University of Technology
2008-2010	Professor of Medicine (apl. Prof.), Dresden University of Technology, Dresden
2009-	Appointment as Adjunct Full Professor of Medicine, Montreal Heart Institute, University of Montreal, Montreal, Canada
01.07.2010	Appointment as Full Professor (W3) of Experimental Cardiology and Chair of Division of Experimental Cardiology, Medical Faculty Mannheim, University Heidelberg, Mannheim, Germany
01.10.2012	Appointment as Full Professor in Pharmacology and Toxicology (W3) and Director, Institute of Pharmacology, Faculty of Medicine, University Duisburg-Essen, Essen, Germany
01.08.2015	Appointment as Adjunct Full Professor of Medicine, Department of Molecular Physiology & Biophysics, Baylor College of Medicine, Houston, USA

Awards and Honours

1999	Poster Award, Annual Meeting of German Society for Experimental and Clinical Pharmacology and Therapy, Berlin
2000	Teaching Award, Gesellschaft von Freunden und Förderern der TU Dresden
2001	Carl Gustav Carus-Teaching Award, Medical Faculty Dresden
2001	Wilhelm P. Winterstein Research Award, German Heart Foundation
2003	Abstract Travel Award, AHA Scientific Sessions, Orlando, USA
2004	Carl Gustav Carus-Teaching Award, Medical Faculty Dresden
2005	Albert-Fraenkel-Award, German Cardiac Society
2010-2015	Work package leader, EU FP7-HEALTH-2010 Large-scale Integrating Project ("The European Network for Translational Research in Atrial Fibrillation"; http://www.eutraf.eu/)
2011-2013	Co-coordinator of Arrhythmia Research Program and Member of Research Coordinating Committee, German Centre for Cardiovascular Research ("Deutsches Zentrum für Herz-Kreislauf Forschung")
2012	Outstanding Achievement Award, European Cardiac Arrhythmia Society
2007-2013	Grantee Coordinator, Transatlantic Networks of Excellence in Cardiovascular Research Program of Fondation Leducq, 07CVD03 ("The European-North American Atrial Fibrillation Research Alliance"; http://www.transatlantic-af-alliance.org/)
2017	Elected Fellow of the International Academy of Cardiovascular Sciences
2018	Honorary Member of Romanian Society of Cardiology
2018	Elected Fellow of the International Society for Heart Research
2020	Rated #2 / #11 (basic / basic+clinical) worldwide expert in Atrial Fibrillation by <i>ExpertScape</i> (ExpertScape.com)

Editorial Boards

2003-	Naunyn Schmiedeberg's Archive of Pharmacology (2005-, <i>Associate Editor</i>)
2004-2019	Journal of Molecular and Cellular Cardiology

2007-	Cardiovascular Research (<i>Guest Editor</i> of spotlight issues: 2011, 2015, and 2020)
2008-16	Circulation: Arrhythmia and Electrophysiology (founding member)
2009-	Journal of Ion Channels
2009-2020	BioMed Research International (<i>Associate Editor</i>)
2009-	Open Journal of Cardiology
2009-	Basic Research in Cardiology
2010-	Frontiers in Cardiac Electrophysiology (<i>Review Editor</i>)
2010-	Pragmatic and Observational Research
2011-	World Journal of Hypertension
2011-	Europace
2012-	Future Cardiology
2013-	Arrhythmia & Electrophysiology Review
2014-2016	Circulation
2015-	European Heart Journal - Cardiovascular Pharmacotherapy
2016-2019	International Journal of Cardiology (<i>Associate Editor</i>)
2017-	<u>International Journal of Cardiology Heart & Vasculature</u> (Editor-in-Chief)
2017-	Journal of Interventional Cardiac Electrophysiology
2018	Canadian Journal of Cardiology (<i>Guest Editor</i>)
2018	International Journal of Cardiology (<i>Guest Editor</i>)
2018	Pharmacological Research (<i>Guest Editor</i>)
2019-	Reviews in Cardiovascular Medicine
2020-	<u>International Journal of Cardiology</u> (Deputy Editor)

Bibliography	(Scopus/GoogleScholar, updated on 25.09.2020)
Total Publications	261
Publications in the Last 5 Years	116
Total Impact Factor	2394.7
Average Impact Factor per Article	9.2
Average Impact Factor per Original Article	10.7
Citations 2017	3347 / 5048
Citations 2018	4039 / 5806
Citations 2019	3592 / 5431
Total Citations	23205 / 36095
<i>h</i> -Index	72 / 81
<i>m</i> -Index = <i>h</i> -Index per Year since First Paper	2.8

Most Important Publications (citations: Scopus/GoogleScholar)

1. **Dobrev D**, et al. & Ravens U (2001) Molecular basis of downregulation of G-protein-coupled inward rectifying K⁺ current (I_{K,ACh}) in chronic human atrial fibrillation: Decrease in GIRK4 mRNA correlates with reduced I_{K,ACh} and muscarinic receptor-mediated shortening of action potentials. **Circulation**, 104: 2551-2557. (242/323 citations)
2. Christ T, et al. & **Dobrev D** (2004) L-type Ca²⁺ current downregulation in chronic human atrial fibrillation is associated with increased activity of protein phosphatases. **Circulation**, 110: 2651-2657. (196/281 citations)
3. **Dobrev D**, et al. & Ravens U (2005) The G-protein gated potassium current I_{K,ACh} is constitutively active in patients with chronic atrial fibrillation. **Circulation**, 112: 3697-3706. (315/440 citations)
4. El-Armouche A, et al. & **Dobrev D** (2006) Molecular determinants of altered Ca²⁺-handling in human chronic atrial fibrillation. **Circulation**, 114: 670-680. (189/257 citations)
5. Nattel S, Burstein B, **Dobrev D** (2008) Atrial remodelling and atrial fibrillation: mechanisms and implications. **Circ Arrhythm Electrophysiol**, 1: 62-73. (610/1319 citations)

6. Chelu MG, et al. & **Dobrev D***, Wehrens XHT* (2009) Calmodulin kinase II-mediated sarcoplasmic reticulum calcium leak promotes atrial fibrillation in mice. *J Clin Invest*, 119: 1940-1951. *shared senior and correspondence authorship (272/351 citations)
7. **Dobrev D**, Nattel S (2010) New antiarrhythmic drugs for treatment of atrial fibrillation. *The Lancet*, 375(9721): 1212-23. (224/301 citations)
8. **Dobrev D**, Carlsson L, Nattel S (2012) Novel molecular targets for atrial fibrillation therapy. *Nat Rev Drug Discov*, 11(4): 275-91. (137/180 citations)
9. Voigt N, et al. & **Dobrev D** (2012) Enhanced sarcoplasmic reticulum Ca²⁺ leak and increased Na⁺-Ca²⁺ exchanger function underlie delayed afterdepolarizations in patients with chronic atrial fibrillation. *Circulation*, 125(17): 2059-70. (317/421 citations)
10. Voigt N, et al. & **Dobrev D** (2014) Cellular and molecular mechanisms of atrial arrhythmogenesis in patients with paroxysmal atrial fibrillation. *Circulation*, 129(2): 145-56. (214/308 citations)
11. Heijman J, Voigt N, Nattel S, **Dobrev D** (2014) Cellular and Molecular Electrophysiology of Atrial Fibrillation Initiation, Maintenance and Progression. *Circ Res*, 114(9): 1483-99. (279/379 citations)
12. Schmidt C, et al. & **Dobrev D***, Thomas D* (2015) Upregulation of K_{2P3.1} K⁺ current causes action potential shortening in patients with chronic atrial fibrillation. *Circulation*, 132(2): 82-92. *shared senior authorship (86/105 citations)
13. Nattel S, **Dobrev D** (2016) Electrophysiological and molecular mechanisms of paroxysmal atrial fibrillation. *Nat Rev Cardiol*, 13(10): 575-90. (60/74 citations)
14. Kirchhof P, Benussi S, Kotecha D, ... **Dobrev D** ... Windecker S, Zamorano JL, Zeppenfeld K (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the ESC. Developed with the special contribution of EHRA of the ESC. Endorsed by the European Stroke Organisation (ESO). *Eur Heart J*, 37: 2893-2962. (3186/6889 citations)
15. Abu-Taha IH, et al. & **Dobrev D#**, Wieland T# (2017) Nucleoside Diphosphate Kinase-C Suppresses cAMP Formation in Human Heart Failure. *Circulation*, 135(9): 881-897. #co-senior and co-correspondence authors. (10/15 citations)
16. Heijman J, Guichard JB, **Dobrev D**, Nattel S (2018) Translational challenges in atrial fibrillation. *Circ Res*, 122(5): 752-773. (43/61 citations)
17. Yao C, Veleza T et al. & **Dobrev D**, Li N (2018) Enhanced NLRP3 Inflammasome Signaling Promotes Atrial Fibrillation. *Circulation*, 138: 2227-2242. (70/84 citations)
18. Molina CE, et al. & **Dobrev D** (2018) Profibrotic, Electrical, and Calcium-Handling Remodeling of the Atria in Heart Failure Patients With and Without Atrial Fibrillation. *Front Physiol*, 9: 1383. (13/18 citations)
19. **Dobrev D**, et al. & Nattel S (2019) Post-operative Atrial Fibrillation: Mechanisms, Manifestations and Management. *Nat Rev Cardiol*, 16(7): 417-436. (15/23 citations)
20. Fender AC, et al. & **Dobrev D** (2020) Thrombin receptor PAR4 drives canonical NLRP3 inflammasome signaling in the heart. *Basic Res Cardiol*, 115(2):10. (2/3 citations)
21. Nattel S, Heijman J, Zhou L, **Dobrev D** (2020) The Molecular Basis of Atrial Fibrillation Pathophysiology and Therapy: A Translational Perspective. *Circ Res*, 127: 51-72. (5/7 citations)
22. Heijman J et al. & **Dobrev D** (2020) Atrial Myocyte NLRP3/CaMKII Nexus Forms a Substrate for Post-operative Atrial Fibrillation. *Circ Res*, 127(8): 1036-1055. (-/2 citations)
23. Campbell HM et al. & **Dobrev D**, Wehrens XHT (2020) Loss of SPEG Inhibitory Phosphorylation of Ryanodine Receptor Type-2 Promotes Atrial Fibrillation. *Circulation*, 142(12): 1159-1172. (-/- citations)
24. Hindricks G, Potpara T, Dagres N... **Dobrev D**... Suwalaki P, Svetlosak M, Touyz RM (2020) 2020 ESC Guidelines for the diagnosis and management of atrial fibrillation developed in

collaboration with the EACTS and the special contribution of the EHRA of the ESC. **Eur Heart J**, Published online on Aug 29, 2020 (<https://doi.org/10.1093/eurheartj/ehaa612>). (-/4 citations)

Funding History as Principal/Co-Principal Investigator (selection): Total amount: approx. 9 Mio. €

2002-2014	DFG, DO 769/1-3 (<i>Mechanisms of Constitutive $I_{K,ACH}$ Channels in AF</i>)
2007-2013	Fondation Leducq, Transatlantic Networks of Excellence in Cardiovascular Research Program, 07CVD03 (<i>European-North American AF Research Alliance</i>) (Grantee Coordinator)
2010-2015	European Union, FP7-HEALTH-2010, large-scale integrating project, Proposal No: 261057 (<i>The European Network for Translational Research in AF, EUTRAF</i>) (Work Package Leader)
2016-2021	NIH, R01 HL131517 (<i>Perturbed Sodium and Calcium Fluxes in AF</i> , with E. Grandi)
2017-2022	DFG, DO 769/4-1 (<i>Molecular Basis and Proarrhythmic Role of SK Channels in AF</i>)
2017-2021	NIH, R01 HL136389 (<i>The Role of Inflammasome in the Pathogenesis of AF</i> , with N. Li)
2019-2023	NIH, R01 HL089598 (<i>Ryanodine Receptor Regulation in postoperative AF</i> , with X. Wehrens)

Major Committees and Professional Services (Selection)

2007-	Member of Scientific Advisory Board, International Academy of Cardiology.
2007-2010	Chair, Working Group on Cellular Electrophysiology, German Society of Cardiology.
2007-2011	Member of Program Committee, German Society of Cardiology.
2007-2008	Member of Program Committee, European Cardiac Arrhythmia Society.
2009-	Member of Scientific Committee, Paul-David Chair in Cardiovascular Electrophysiology, Montreal Heart Institute, University of Montreal, Canada.
2010	Member of Scientific Programs Committee, CARDIOSTIM 2010, 17 th World Congress in Cardiac Electrophysiology and Cardiac Techniques, 16-19 June, Nice, France.
2010-2011	Member of Program Committee, European Heart Rhythm Association (EHRA), Europace 2011, Madrid, Spain.
2010-2011	Member of Organizing Committee, "Up-date on Arrhythmias: 25 Years of Radiofrequency Ablation". Rosengarten Conference Center Mannheim, September 15–17, 2011, Mannheim, Germany.
2011-2013	Scientific Representative/Principal Investigator of Medical Faculty Mannheim in the German (National) Centre for Cardiovascular Research.
2011-2013	Co-Coordinator of "Arrhythmia" Research Programme of the German (National) Centre for Cardiovascular Research.
2012-2013	Member of Program Committee of the Annual Meeting of the ESC Working Group on Cardiac Cellular Electrophysiology, 23-24.06.2013, Athens, Greece.
2014-2016	Member of Programme Committee of ESC Frontiers in CardioVascular Biology Meeting 2016, Florence, Italy.
2013-2014	Reviewer, 2014 ESC/EACTS Guidelines on myocardial revascularization: the Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS).
2014-2015	Reviewer, 2015 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: The Task Force for the Management of Patients with Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death of the European Society of Cardiology (ESC) Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC).
2015-2016	Member of Congress Programme Committee, European Society of Cardiology, Annual Meeting Rome 2016.
2015-2016	Reviewer, ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS: The Task Force for the management of atrial fibrillation of the ESC. Developed with the special contribution of EHRA of the ESC. Endorsed by the European Stroke Organisation (ESO).

2015-2016	Member of Writing Committee, Position Paper on <i>Atrial Cardiomyopathies: Definition, Characterization and Clinical Implication</i> , a joint initiative of EHRA, HRS, APHRS and SOLAEGE.
2016-	Council Member, European Section of International Academy of Cardiovascular Sciences.
2017-	Member of Programme Committee of EHRA Annual Meeting 2018, Barcelona, Spain.
2016-2018	Chair, Working Group on Cardiac Cellular Electrophysiology, European Society of Cardiology.
2017-2020	Board Member of European Heart Rhythm Association.
2018-2021	Member of Executive Council, International Academy of Cardiovascular Sciences.
2018	Chairman, Annual Meeting of the ESC Working Group on Cardiac Cellular Electrophysiology, Essen, Germany.
2018-2019	Program Committee Chairman, Annual Meeting of European Cardiac Arrhythmia Society 2019, June 16-18, Marseille, France.
2018-2020	Past-Chair, Working Group on Cardiac Cellular Electrophysiology, European Society of Cardiology.
2018-2020	Member of Council on Basic Cardiovascular Science, European Society of Cardiology.
2019-2020	Member of Programme Committee, FCVB 2020, Budapest, Hungary (postponed to 2021).
2019-2023	Member of Nominating Committee, German Society of Cardiology.
2020	Member of Nominating Committee, Working Group on Cardiac Cellular Electrophysiology European Society of Cardiology.
2020-2024	Nucleus Member, Working Group on Cardiovascular Pharmacotherapy, European Society of Cardiology.